Among a cohort of Chinese patients with gout, dotinurad 4 mg demonstrated superiority to febuxostat 40 mg in lowering serum uric acid (sUA), according to data presented at the 2024 European Congress of Rheumatology (EULAR). Additionally, dotinurad 2 mg was non-inferior to febuxostat and the drug was well tolerated.

“Gout is increasingly common disease in China,” explained a team of international investigators.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/dotinurad-demonstrates-superiority-to-febuxostat-for-the-treatment-of-gout